Journals / Balkan Medical Journal / 2013 / Cilt: 30 - Sayı: 3

The Status of Telomerase Enzyme Activity in Benign and Malignant Gynaecologic Pathologies

Pages
287–292
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With the presence of these data, sensitivity and specificity of hTERT for the diagnosis of malignancy were calculated to be 88.9% and 91.9%, respectively.Conclusion: It was suggested that the measurement of telomerase activity in gynaecologic tumors, except for endometrial tissue in the reproductive phase, is a valuable method for pathological investigation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Telomeres are essential for the function and stability of eukaryotic chromosomes.
📊
Key Findings & Data:Telomerase consists of three subunits: human telomerase reverse transcriptase (hTERT), human telomerase RNA (hTR), and telomerase protein 1 (TP1).
💡
Conclusion & Impact:With the presence of these data, sensitivity and specificity of hTERT for the diagnosis of malignancy were calculated to be 88.9% and 91.9%, respectively.Conclusion: It was suggested that the measurement of telomerase activity in gynaecologic tumors, except for endometrial tissue in the reproductive phase, is a valuable method for pathological investigation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Telomeres are essential for the function and stability of eukaryotic chromosomes. Telomerase consists of three subunits: human telomerase reverse transcriptase (hTERT), human telomerase RNA (hTR), and telomerase protein 1 (TP1). The hTERT subunit determines the activity of telomerase as an enzyme and is detected in most human tumors and regenerative cells. Telomerase activity is a useful cancer-cell detecting marker in some types of cancers.Aims: The aim of this study was to assess of telomerase hTERT mRNA in gynaecological tumors for diagnosis of malignancy.Study Design: Cross-sectional study.Methods: A total of 55 gynaecologic tumor samples (35 ovarian, 13 endometrial, 6 cervical and 1 placental site trophoblastic tumor tissue) were obtained at the time of surgery. Quantification of hTERT mRNA was performed in a real-time reverse transcriptase polymerase chain reaction (RT-PCR) using the LightCycler TeloTAGGG hTERT Quantification Kit.Results: It was histopathologically detected that 18 of the tissue samples were malignant and 37 of the samples were benign. 16 of the malignant tissue samples (88.9%) and 3 (8.1%) (endometrial tissue in proliferative phase, mucinous cyst adenoma and endometriosis) of the benign tissue samples were found to be hTERT positive. With the presence of these data, sensitivity and specificity of hTERT for the diagnosis of malignancy were calculated to be 88.9% and 91.9%, respectively.Conclusion: It was suggested that the measurement of telomerase activity in gynaecologic tumors, except for endometrial tissue in the reproductive phase, is a valuable method for pathological investigation.

🔖

Cite This Article

TÜTÜNCÜ, L., TUNCA, Y., BODUR, S., GÜL, İ., DÜNDAR, Ö. (2022). The Status of Telomerase Enzyme Activity in Benign and Malignant Gynaecologic Pathologies. Balkan Medical Journal, Cilt: 30 - Sayı: 3, 287–292. https://ajindex.com/articles/461578

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am 1996
  2. [CrossRef] 2. Blackburn EH. Switching and signaling at the telomere. Cell 2001
  3. [CrossRef] 3. Goldstein S. Replicative Senescence: The Human Fibroblast Comes of Age. Science 1990
  4. [CrossRef] 4. Shay JW, Zou Y, Hiyama E, Wrigw E. Telomerase and Cancer. Hum Mol Genet 2001
  5. [CrossRef] 5. Shay JW, Bacchetti S. A survey of Telomerase Activity in Human Cancer. Eur J Cancer 1997
  6. [CrossRef] 6. Miura N, Kanamori Y, Takahashi M, Sato R, Tsukamoto T, Takahashi S, et al. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. 2007
  7. Carroll KA, Ly H. Functional characterization of mutations in the promoter proximal region of the telomerase hTERC gene identi- fied in patients with hematological disorders. Int J Clin Exp Med 2011
  8. Adler S, Rashid G, Klein A. Indole-3-carbinol inhibits telomerase activity and gene expression in prostate cancer cell lines. Anticancer Res 2011
  9. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001
  10. [CrossRef] 10. Jarboe EA, Liaw KL, Thompson LC, Heinz DE, Baker PL, McGregor JA, et al. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene 2002
  11. [CrossRef] 11. Mutirangura A, Sriuranpong V, Termrunggraunglert W, Tresukosol D, Lertsaguansinchai P, Voravud N, et al. Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions. Br J Cancer 1998
  12. [CrossRef] 12. Nagai N, Oshita T, Murakami J, Ohama K. Semiquantitative analysis of telomerase activity in cervical cancer and precancerous lesions. Oncol Rep 1999
  13. Wisman GBA, Hollema H, de Jong S, ter Schegget J, Tjong-AHung SP, Ruiters MHJ, et al. Telomerase activity as biomarker for (pre)-neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smears. J Clin Oncol 1998
  14. Lehner R, Enomoto T, McGregor JA, Shroyer AL, Haugen BR, Pugazhenthi U, et al. Quantitative Analysis of Telomerase hTERT mRNA and TelomeraseActivity in Endometrioid Adenocarcinoma and in Normal Endometrium. Gynecologic Oncology 2002
  15. [CrossRef] 15. Shroyer KR, Stephens JK, Silver